CN110831933A - 喹唑啉衍生物作为突变kras、hras或nras的调节剂 - Google Patents

喹唑啉衍生物作为突变kras、hras或nras的调节剂 Download PDF

Info

Publication number
CN110831933A
CN110831933A CN201880034310.1A CN201880034310A CN110831933A CN 110831933 A CN110831933 A CN 110831933A CN 201880034310 A CN201880034310 A CN 201880034310A CN 110831933 A CN110831933 A CN 110831933A
Authority
CN
China
Prior art keywords
compound
alkyl
cancer
group
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880034310.1A
Other languages
English (en)
Chinese (zh)
Inventor
李连升
冯军
吴涛
刘源
王祎
任平达
刘毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Araxes Pharma LLC
Original Assignee
Araxes Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araxes Pharma LLC filed Critical Araxes Pharma LLC
Publication of CN110831933A publication Critical patent/CN110831933A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880034310.1A 2017-05-25 2018-05-24 喹唑啉衍生物作为突变kras、hras或nras的调节剂 Pending CN110831933A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511152P 2017-05-25 2017-05-25
US62/511,152 2017-05-25
PCT/US2018/034470 WO2018218069A1 (en) 2017-05-25 2018-05-24 Quinazoline derivatives as modulators of mutant kras, hras or nras

Publications (1)

Publication Number Publication Date
CN110831933A true CN110831933A (zh) 2020-02-21

Family

ID=62621033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034310.1A Pending CN110831933A (zh) 2017-05-25 2018-05-24 喹唑啉衍生物作为突变kras、hras或nras的调节剂

Country Status (5)

Country Link
US (1) US11639346B2 (enExample)
EP (1) EP3630747A1 (enExample)
JP (1) JP2020521740A (enExample)
CN (1) CN110831933A (enExample)
WO (1) WO2018218069A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249475A1 (zh) * 2020-06-10 2021-12-16 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
WO2022063297A1 (zh) * 2020-09-27 2022-03-31 微境生物医药科技(上海)有限公司 喹唑啉衍生物及其制备方法和用途
WO2022068921A1 (zh) * 2020-09-30 2022-04-07 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
WO2022135470A1 (zh) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
CN116963733A (zh) * 2020-12-02 2023-10-27 斯汀格瑞治疗股份有限公司 作为enpp1抑制剂的咪唑化合物
WO2024022471A1 (zh) * 2022-07-28 2024-02-01 上海湃隆生物科技有限公司 Kras抑制剂化合物

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
KR20240113606A (ko) 2015-11-16 2024-07-22 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
SG11201906223TA (en) 2016-12-22 2019-08-27 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
KR20200010306A (ko) * 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
CA3099045A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
MX2020012731A (es) 2018-06-01 2021-02-22 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
TWI831855B (zh) 2018-10-26 2024-02-11 日商大鵬藥品工業股份有限公司 新穎吲唑化合物或其鹽
IL282916B2 (en) 2018-11-09 2024-09-01 Hoffmann La Roche Fused cyclic chemical compounds and their uses in the treatment of ras-mediated diorders
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CR20210504A (es) 2019-03-05 2022-02-08 Astrazeneca Ab Compuestos tricíclicos condensados útiles como agentes anticancerígenos
CN111773225A (zh) * 2019-04-04 2020-10-16 山东轩竹医药科技有限公司 Kras及其突变体表达抑制剂
AU2020260629A1 (en) * 2019-04-22 2021-12-09 Betta Pharmaceuticals Co., Ltd Quinazoline compound and pharmaceutical application thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CN118834208A (zh) 2019-05-21 2024-10-25 美国安进公司 固态形式
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021058018A1 (en) * 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
CN112574224A (zh) * 2019-09-30 2021-03-30 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用
PH12022551027A1 (en) 2019-10-28 2023-05-29 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12c mutant
MX2022005357A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106230A1 (ja) 2019-11-29 2021-06-03 大鵬薬品工業株式会社 新規なフェノール化合物又はその塩
GB202001344D0 (en) 2020-01-31 2020-03-18 Redx Pharma Plc Ras Inhibitors
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
BR112022025550A2 (pt) 2020-06-18 2023-03-07 Revolution Medicines Inc Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
IL301524A (en) 2020-09-23 2023-05-01 Erasca Inc Tricyclic pyridones and pyrimidones
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
JP7737455B2 (ja) * 2020-12-22 2025-09-10 ハンミ ファーマシューティカル カンパニー リミテッド Ｓｏｓ１阻害剤としての新規キナゾリン誘導体化合物及びその用途｛ｎｏｖｅｌ ｑｕｉｎａｚｏｌｉｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｓ ｓｏｓ１ ｉｎｈｉｂｉｔｏｒｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝
MX2023013085A (es) 2021-05-05 2023-11-16 Revolution Medicines Inc Inhibidores de ras.
US12252497B2 (en) 2021-05-05 2025-03-18 Revolution Medicines, Inc. Ras inhibitors
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
JP2024532374A (ja) 2021-09-01 2024-09-05 ノバルティス アーゲー Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US20240409558A1 (en) * 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
GB202212641D0 (en) 2022-08-31 2022-10-12 Jazz Pharmaceuticals Ireland Ltd Novel compounds
AU2023377064A1 (en) 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2024158778A1 (en) * 2023-01-24 2024-08-02 Theras, Inc. Compositions and methods for inhibition of ras
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054572A1 (en) * 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c
WO2016164675A1 (en) * 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof

Family Cites Families (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB939516A (en) 1961-05-29 1963-10-16 British Drug Houses Ltd Sulphonyl ureas
US3702849A (en) 1967-10-26 1972-11-14 Pfizer 4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters
US3752660A (en) 1971-03-15 1973-08-14 Allied Chem Chlorophenoxyacetyloxazolidone herbicides and preparation thereof
US4436748A (en) 1980-10-20 1984-03-13 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]thiophenes
EP0094498A3 (en) 1982-05-06 1985-04-03 American Cyanamid Company Antiatherosclerotic 1-piperazine derivatives
US4439606A (en) 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
US4656181A (en) 1982-11-24 1987-04-07 Cermol S.A. Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same
JPS59163372A (ja) 1983-03-09 1984-09-14 Showa Denko Kk ピラゾ−ル誘導体とその製造法及び除草剤
JPS60193955A (ja) 1984-03-13 1985-10-02 Mitsui Toatsu Chem Inc 環式不飽和アミド置換エ−テル化合物及びその製造方法
JPS6143190A (ja) 1984-08-06 1986-03-01 Mitsui Petrochem Ind Ltd ピリドピリミジン誘導体およびその製法
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6017696A (en) 1993-11-01 2000-01-25 Nanogen, Inc. Methods for electronic stringency control for molecular biological analysis and diagnostics
US6051380A (en) 1993-11-01 2000-04-18 Nanogen, Inc. Methods and procedures for molecular biological analysis and diagnostics
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
DE69531542T2 (de) 1994-02-07 2004-06-24 Beckman Coulter, Inc., Fullerton Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JP2002515008A (ja) 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (pt) 1995-04-20 2001-04-30 Pfizer Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
FR2734816B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux aryl (alkyl) propylamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
YU1899A (sh) 1996-07-18 2000-03-21 Pfizer Inc. Inhibitori matričnih metaloproteaza na bazi fosfinata
JP2000501423A (ja) 1996-08-23 2000-02-08 ファイザー インク． アリールスルホニルアミノヒドロキサム酸誘導体
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
EP0950059B1 (en) 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
SK283963B6 (sk) 1997-02-03 2004-06-08 Pfizer Products Inc. Deriváty arylsulfonylaminohydroxamovej kyseliny, farmaceutický prostriedok, spôsob inhibície matričných metaloproteináz alebo produkcie faktora nekrózy nádorov
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
ID22809A (id) 1997-02-11 1999-12-09 Pfizer Turunan-turunan asam arilsulfonil hidroksamat
WO1998035951A2 (en) 1997-02-17 1998-08-20 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
CN1267291A (zh) 1997-06-17 2000-09-20 先灵公司 新的n－取代的脲的法呢基蛋白转移酶抑制剂
AU730248B2 (en) 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
DE19756236A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
IL136637A0 (en) 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
CA2335951C (en) 1998-06-24 2013-07-30 Mark S. Chee Decoding of array sensors with microspheres
DE69915004T2 (de) 1998-11-05 2004-09-09 Pfizer Products Inc., Groton 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
NZ517121A (en) 1999-09-13 2004-05-28 Nugen Technologies Inc Methods and compositions for linear isothermal amplification of polynucleotide sequences
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
DK1263503T3 (da) 2000-03-13 2006-02-13 Wyeth Corp Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper
AU2001245863A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
EP1289984A4 (en) 2000-06-05 2004-11-24 Dong A Pharm Co Ltd NEW OXAZOLIDE DERIVATIVES AND A METHOD FOR THEIR PRODUCTION
TWI227231B (en) 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
KR100831116B1 (ko) 2000-08-18 2008-05-20 밀레니엄 파머슈티컬스 인코퍼레이티드 키나아제 억제제로서의 퀴나졸린 유도체
US6890747B2 (en) 2000-10-23 2005-05-10 Warner-Lambert Company Phosphoinositide 3-kinases
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US20020169300A1 (en) 2001-01-30 2002-11-14 Waterman Marian L. Method of detection and treatment of colon cancer by analysis of beta-catenin-sensitive isoforms of lymphoid enhancer factor-1
AU2002338334B8 (en) 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
ATE402164T1 (de) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
DE60234453D1 (de) 2001-07-02 2009-12-31 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
WO2003053958A1 (en) 2001-12-20 2003-07-03 Celltech R & D Limited Quinazolinedione derivatives
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
EP1556349A1 (en) 2002-10-11 2005-07-27 Astrazeneca AB 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
JP4608852B2 (ja) 2002-10-15 2011-01-12 チッソ株式会社 液晶性ビニルケトン誘導体およびその重合体
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
WO2004074283A1 (en) 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
KR101146806B1 (ko) 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
US20050119266A1 (en) 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
JP4923380B2 (ja) 2003-12-22 2012-04-25 Ｊｎｃ株式会社 低屈折率異方性化合物、組成物およびそれらの重合体または重合体組成物
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
WO2005082892A2 (en) 2004-02-17 2005-09-09 Dr. Reddy's Laboratories Ltd. Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
GB0405628D0 (en) 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
GT200500375A (es) 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
US20090264415A2 (en) 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
JP4955646B2 (ja) 2005-03-16 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー シス−２，４，５−トリアリール−イミダゾリン及びそれらの抗癌薬としての使用
JP2007016011A (ja) 2005-06-10 2007-01-25 Nippon Soda Co Ltd 抗酸化活性を有する新規な含窒素ヘテロ環化合物、及び該化合物を含有する抗酸化薬
CA2612788A1 (en) 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
BRPI0617271A2 (pt) 2005-10-11 2011-07-19 Intermune Inc inibidores de replicação viral
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
CA2632030A1 (en) 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP1981848A2 (en) 2006-02-07 2008-10-22 Wyeth 11-beta hsd1 inhibitors
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
WO2007113226A1 (en) 2006-03-31 2007-10-11 Novartis Ag Organic compounds
CA2647448A1 (en) 2006-04-12 2007-10-18 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
EP2038255A2 (en) 2006-06-16 2009-03-25 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted piperidine carboxamides
ATE456565T1 (de) 2006-06-22 2010-02-15 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
FR2903101B1 (fr) 2006-06-30 2008-09-26 Servier Lab Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN101790527A (zh) 2006-07-20 2010-07-28 凯利普西斯公司 Rho激酶的苯并噻吩抑制剂
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
EP1903038A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren
CA2663501A1 (en) 2006-09-15 2008-03-20 Schering Corporation Treating pain, diabetes, and disorders of lipid metabolism
US20100144710A1 (en) 2007-03-09 2010-06-10 Astrazeneca Ab Piperazine and Piperidine MGLUR5 Potentiators
MX2009011211A (es) 2007-04-16 2009-10-30 Abbott Lab Indoles sustituidos en la posicion 7 inhibidores de mci-1.
EP3425060B1 (en) 2008-03-28 2021-10-27 Pacific Biosciences of California, Inc. Compositions and methods for nucleic acid sequencing
EP2133334A1 (en) 2008-06-09 2009-12-16 DAC S.r.l. Heterocyclic derivatives as HDAC inhibitors
CA2733533C (en) 2008-08-25 2013-12-17 Irm Llc Hedgehog pathway modulators
EP2370424A1 (en) 2008-11-10 2011-10-05 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2010087399A1 (ja) 2009-01-30 2010-08-05 第一三共株式会社 ウロテンシンｉｉ受容体拮抗薬
CN102459240A (zh) 2009-04-22 2012-05-16 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的氮杂环丁烷基二酰胺
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
EP2270002A1 (en) 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
DK2448581T3 (en) 2009-06-29 2017-03-13 Agios Pharmaceuticals Inc Therapeutic compositions and methods for their applications
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
CN102625708A (zh) 2009-09-09 2012-08-01 阿维拉制药公司 Pi3激酶抑制剂及其用途
US20120040950A1 (en) 2009-12-22 2012-02-16 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
CA2785738A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
RS53705B1 (sr) 2010-01-29 2015-04-30 Otsuka Pharmaceutical Co., Ltd. Di-supstituisani piridinski derivati kao antikancerska sredstva
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
WO2011113512A1 (de) 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
CN102770414A (zh) 2010-04-28 2012-11-07 第一三共株式会社 ［5,6］杂环化合物
TW201202230A (en) 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2011156529A2 (en) 2010-06-08 2011-12-15 Nugen Technologies, Inc. Methods and composition for multiplex sequencing
US8658131B2 (en) 2010-06-21 2014-02-25 Washington University Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand
KR101826382B1 (ko) 2010-07-30 2018-02-06 온코세라피 사이언스 가부시키가이샤 퀴놀린 유도체 및 이를 함유하는 ｍｅｌｋ 억제제
CN103068798A (zh) 2010-09-03 2013-04-24 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的二-氮杂环丁烷二酰胺
AR083199A1 (es) 2010-09-29 2013-02-06 Intervet Internationale B V Compuestos de n-heteroarilo con unidad de puente ciclico
CN103260703A (zh) 2010-10-22 2013-08-21 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的哌啶-4-基-氮杂环丁烷二酰胺
US20130225524A1 (en) 2010-11-05 2013-08-29 Deping Chai Chemical Compounds
US9260484B2 (en) 2011-06-15 2016-02-16 Ohio State Innovation Foundation Small molecule composite surfaces as inhibitors of protein-protein interactions
US20140315886A1 (en) 2011-06-29 2014-10-23 Otsuka Pharmaceutical Co., Ltd. Quinazolines as therapeutic compounds and related methods of use
CN103087077B (zh) 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
JP2013107855A (ja) 2011-11-22 2013-06-06 Mitsubishi Tanabe Pharma Corp 医薬組成物
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013096151A1 (en) 2011-12-22 2013-06-27 Glaxosmithkline Llc Chemical compounds
WO2013106641A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013140148A1 (en) 2012-03-19 2013-09-26 Imperial Innovations Limited Quinazoline compounds and their use in therapy
WO2013155077A1 (en) 2012-04-09 2013-10-17 Board Of Regents,The University Of Texas System Response markers for src inhibitor therapies
US20150087628A1 (en) 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
CA2872930A1 (en) 2012-05-09 2013-11-14 Gradalis, Inc. Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
PT2872491T (pt) 2012-07-11 2021-08-05 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
JPWO2014030743A1 (ja) 2012-08-24 2016-08-08 武田薬品工業株式会社 複素環化合物
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP2922851B8 (en) 2012-11-20 2017-09-27 F. Hoffmann-La Roche AG Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
US9695179B2 (en) 2013-03-14 2017-07-04 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
CA2903813C (en) 2013-03-15 2023-08-29 Epizyme, Inc. Carm1 inhibitors and uses thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US20150330990A1 (en) 2013-06-13 2015-11-19 Biodesy, Inc. Method of screening candidate biochemical entities targeting a target biochemical entity
BR112015032330B1 (pt) 2013-06-26 2019-01-22 Abbvie Inc. carboxamidas primárias como inibidores de bkt
US20150005277A1 (en) 2013-06-28 2015-01-01 Beigene, Ltd. Protein Kinase Inhibitors and Uses Thereof
CA2917315C (en) 2013-07-03 2021-10-05 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
SG11201600159TA (en) 2013-07-31 2016-02-26 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
CN104418860B (zh) 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
US9550770B2 (en) 2013-08-23 2017-01-24 Neupharma, Inc. Substituted quinazolines for inhibiting kinase activity
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
US9376559B2 (en) 2013-11-22 2016-06-28 Exxonmobil Chemical Patents Inc. Reverse staged impact copolymers
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
EA201691302A1 (ru) 2014-02-03 2017-03-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
CA2943220C (en) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
KR101910724B1 (ko) 2014-03-24 2018-10-22 광동 쫑성 파마세티컬 컴패니, 리미티드 Smo 억제제로서의 퀴놀린 유도체
WO2015184349A2 (en) 2014-05-30 2015-12-03 The Trustees Of Columbia University In The City Of New York Multivalent ras binding compounds
EP3160486B1 (en) 2014-06-27 2020-11-18 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
EP3193608A4 (en) 2014-09-17 2018-05-02 Epizyme, Inc. Carm1 inhibitors and uses thereof
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
EP3197870B1 (en) 2014-09-25 2020-08-19 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
PE20171057A1 (es) 2014-10-08 2017-07-21 Hoffmann La Roche Derivados espirodiamina como inhibidores de la aldosterona sintasa
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
MX2017009571A (es) 2015-01-23 2018-09-27 Aclaris Therapeutics Inc Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
WO2016133935A1 (en) 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2016161361A1 (en) 2015-04-03 2016-10-06 Nantbioscience, Inc. Compositions and methods of targeting mutant k-ras
WO2016168540A1 (en) 2015-04-15 2016-10-20 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof
WO2016178110A1 (en) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
WO2017068412A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
KR20240113606A (ko) * 2015-11-16 2024-07-22 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
CN105348271A (zh) 2015-12-23 2016-02-24 常州润诺生物科技有限公司 喹唑啉类衍生物药用用途及其制备方法
CN105399734A (zh) 2015-12-23 2016-03-16 吉林省长源药业有限公司 新型egfr抑制剂及其制备方法
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN105924840A (zh) 2016-06-01 2016-09-07 扬州兰都塑料科技有限公司 一种阻燃电力电缆
CN106084164A (zh) 2016-06-12 2016-11-09 四川大学 一种结构抗菌型聚氨酯用扩链剂的制备方法
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
MX392031B (es) 2016-11-03 2025-03-21 Corvus Pharmaceuticals Inc Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US20200385364A1 (en) 2017-01-26 2020-12-10 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
KR20200010306A (ko) * 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CA3117210A1 (en) 2018-10-24 2020-04-30 Araxes Pharma Llc 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
US20220112192A1 (en) 2018-11-29 2022-04-14 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054572A1 (en) * 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c
CN106488910A (zh) * 2013-10-10 2017-03-08 亚瑞克西斯制药公司 Kras g12c的抑制剂
WO2016164675A1 (en) * 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249475A1 (zh) * 2020-06-10 2021-12-16 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
WO2022063297A1 (zh) * 2020-09-27 2022-03-31 微境生物医药科技(上海)有限公司 喹唑啉衍生物及其制备方法和用途
CN116390728B (zh) * 2020-09-27 2024-03-29 微境生物医药科技(上海)有限公司 喹唑啉衍生物及其制备方法和用途
CN116390728A (zh) * 2020-09-27 2023-07-04 微境生物医药科技(上海)有限公司 喹唑啉衍生物及其制备方法和用途
WO2022068921A1 (zh) * 2020-09-30 2022-04-07 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
CN116323624A (zh) * 2020-09-30 2023-06-23 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
CN116963733A (zh) * 2020-12-02 2023-10-27 斯汀格瑞治疗股份有限公司 作为enpp1抑制剂的咪唑化合物
WO2022135470A1 (zh) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
CN116648452A (zh) * 2020-12-22 2023-08-25 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
AU2021407653A9 (en) * 2020-12-22 2024-09-19 Shanghai Kechow Pharma, Inc Preparation and application method of heterocyclic compound as kras inhibitor
AU2021407653B2 (en) * 2020-12-22 2025-05-29 Shanghai Kechow Pharma, Inc Preparation and application method of heterocyclic compound as kras inhibitor
AU2021407653B9 (en) * 2020-12-22 2025-06-05 Shanghai Kechow Pharma, Inc Preparation and application method of heterocyclic compound as kras inhibitor
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
WO2024022471A1 (zh) * 2022-07-28 2024-02-01 上海湃隆生物科技有限公司 Kras抑制剂化合物
CN119585288A (zh) * 2022-07-28 2025-03-07 上海湃隆生物科技有限公司 Kras抑制剂化合物

Also Published As

Publication number Publication date
US20200115363A1 (en) 2020-04-16
JP2020521740A (ja) 2020-07-27
WO2018218069A1 (en) 2018-11-29
EP3630747A1 (en) 2020-04-08
US11639346B2 (en) 2023-05-02

Similar Documents

Publication Publication Date Title
JP7628305B2 (ja) 腫瘍転移を阻害するためのｇ１２ｃ変異体ｋｒａｓタンパク質の阻害剤としての２－（２－アクリロイル－２，６－ジアザスピロ［３．４］オクタン－６－イル）－６－（１ｈ－インダゾール－４－イル）－ベンゾニトリル誘導体および関連化合物
US10723738B2 (en) Inhibitors of KRAS G12C mutant proteins
US11639346B2 (en) Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
US10736897B2 (en) Compounds and methods of use thereof for treatment of cancer
JP7327802B2 (ja) 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US20230147053A1 (en) Fused n-heterocyclic compounds and methods of use thereof
US10428064B2 (en) Fused-tricyclic inhibitors of KRAS and methods of use thereof
CN113227092A (zh) 化合物及其用于治疗癌症的使用方法
WO2020028706A1 (en) Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CN110869358A (zh) Kras的共价抑制剂
WO2018140513A1 (en) 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573970A1 (en) 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573954A1 (en) Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
HK40025457A (en) Compounds and methods of use thereof for treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200221